Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-21

FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals, incorporating changes to the approved labeling/ind…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cosentyx (secukinumab)

Snippet

SUPPL AP for COSENTYX (SECUKINUMAB)